Skip to content

Study · Not a test of the peptide alone · 2023

10 results

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.

Wong G, Garner EM, Srivastava G

JCEM case reports1 Mar 2023Cited by 10 (Europe PMC)

PMID37908483 (opens in a new tab)PMCIDPMC10580416 (opens in a new tab)DOI10.1210/jcemcr/luad040 (opens in a new tab)PepBankPUB-37908483
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In three patients with type 1 diabetes and obesity given a GLP-1 receptor agonist and pramlintide, no significant side effects were experienced.

    In plain wordsIn three people with type 1 diabetes and obesity given a GLP-1 drug with pramlintide, no significant side effects occurred.

    Peptide
    Semaglutide
    Outcome
    No significant changeSide effects
    Study

    n = 3

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No significant side effects were experienced.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In three patients with type 1 diabetes and obesity given a GLP-1 receptor agonist and pramlintide, hemoglobin A1c remained constant or decreased during treatment.

    In plain wordsIn three people with type 1 diabetes given a GLP-1 drug with pramlintide, HbA1c stayed the same or went down.

    Peptide
    Semaglutide
    Outcome
    MixedHemoglobin A1c
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    hemoglobin A1c levels remained constant or decreased throughout the treatment period.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesSafety outcome

    In three patients with type 1 diabetes and obesity, GLP-1 receptor agonist and pramlintide regimens produced no significant side effects.

    In plain wordsIn patients with diabetes and obesity, GLP-1 receptor agonist and pramlintide regimens produced no significant side effects.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSignificant side effects
    Study

    n = 3

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No significant side effects were experienced.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 04HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesEfficacy outcome

    All patients with type 1 diabetes and obesity reported lower insulin requirements during GLP-1 receptor agonist and pramlintide treatment.

    In plain wordsPatients with diabetes and obesity reported lower insulin needs during GLP-1 receptor agonist and pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseInsulin requirements
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    All patients reported decreased insulin requirements on pramlintide
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  5. 05HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesEfficacy outcome

    In patients with type 1 diabetes and obesity, hemoglobin A1c remained constant or decreased during GLP-1 receptor agonist and pramlintide treatment.

    In plain wordsIn patients with diabetes and obesity, blood sugar markers stayed constant or decreased during GLP-1 receptor agonist and pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    MixedHemoglobin A1c
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    hemoglobin A1c levels remained constant or decreased throughout the treatment period.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  6. 06HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 32-year-old man with type 1 diabetes, obesity and sleep apnea, semaglutide plus pramlintide was followed by a 20.9 kg weight loss (16.1% of total body weight) over 10 months.

    In plain wordsIn one man with type 1 diabetes and obesity, semaglutide with pramlintide was followed by a 20.9 kg weight loss over 10 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in case 1
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −20.9 kg
    case 1
    Total body weight change
    −16.1%
    case 1

    Source sentences

    Summary
    A 32-year-old male with obstructive sleep apnea (OSA) who lost -20.9 kg (-16.1% of total body weight [TBW]) over 10 months on semaglutide and pramlintide.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 49-year-old woman with type 1 diabetes and obesity, semaglutide plus pramlintide was followed by a 14.6 kg weight loss (17.9% of total body weight) over 6 months.

    In plain wordsIn one woman with type 1 diabetes and obesity, semaglutide with pramlintide was followed by a 14.6 kg weight loss over 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in case 3
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −14.6 kg
    case 3
    Total body weight change
    −17.9%
    case 3

    Source sentences

    Summary
    A 49-year-old female with hypertension, hypothyroidism, and depression who lost -14.6 kg (-17.9% TBW) over 6 months on semaglutide and pramlintide.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesEfficacy outcome

    In a man with type 1 diabetes and obesity, semaglutide and pramlintide reduced body weight over 10 months.

    In plain wordsIn a man with diabetes and obesity, semaglutide and pramlintide reduced weight over 10 months.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCase 1 body weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −20.9 kg
    case 1
    Total body weight change
    −16.1%
    case 1

    Source sentences

    Summary
    A 32-year-old male with obstructive sleep apnea (OSA) who lost -20.9 kg (-16.1% of total body weight [TBW]) over 10 months on semaglutide and pramlintide.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  9. 09HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesEfficacy outcome

    In a woman with type 1 diabetes and obesity, adding dulaglutide and pramlintide after topiramate reduced weight further.

    In plain wordsIn a woman with diabetes and obesity, adding dulaglutide and pramlintide after topiramate reduced weight further.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCase 2 body weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Additional weight change
    −12.8 kg
    case 2 after addition
    Additional total body weight change
    −14%
    case 2 after addition
    Total weight change
    −21.2 kg
    case 2 entire regimen
    Total body weight change
    −23.1%
    case 2 entire regimen

    Source sentences

    Summary
    After adding dulaglutide and pramlintide, she lost an additional -12.8 kg (-14.0% TBW) over 7 months, with total weight loss of -21.2 kg (-23.1% TBW).
    2 context sentences
    Summary · context
    A 68-year-old female with diabetic retinopathy, coronary artery disease, hypertension, hypothyroidism, and depression/anxiety initially treated with topiramate, losing -8.4 kg, but experiencing weight plateau.
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  10. 10HumanNot a test of Pramlintide (Symlin) aloneCase report or seriesEfficacy outcome

    In a woman with type 1 diabetes and obesity, semaglutide and pramlintide reduced weight over 6 months.

    In plain wordsIn a woman with diabetes and obesity, semaglutide and pramlintide reduced weight over 6 months.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCase 3 body weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −14.6 kg
    case 3
    Total body weight change
    −17.9%
    case 3

    Source sentences

    Summary
    A 49-year-old female with hypertension, hypothyroidism, and depression who lost -14.6 kg (-17.9% TBW) over 6 months on semaglutide and pramlintide.
    1 context sentence
    Summary · context
    We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:50 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.